Your SlideShare is downloading. ×
0
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Dugo Iasgo 09
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Dugo Iasgo 09

426

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
426
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • IMPORTANZA ASSOLUTA DI UN VERO CONTROLLO LOCO-REGIONALE DELLA MALATTIA !!!
  • This observation suggests that surgeons might have more of an impact on patient survival by achieving a low-MI operation than a particular D level
  • PERSINO NEL CA MAMMARIO SI STA RIDEFINENDO L’IMPORTANZA DELL’EXERESI LINFATICA NON SOLO COME PROCEDURA STADIATIVA MA COME MOMENTO ESSENZIALE DELLA BONIFICA LOCO-REGIONALE
  • Aggiornamento a 7 anni dopo che nel 2004 abbiamo pubblicato i dati a 3 anni Sopravvivenza mediana: 40 mesi ATTESA: 12 settimane
  • .
  • Studio di fase II condotto dal 1999 al 2004 su 49 pazienti Follow-up breve: solo 18 mesi ATTESA: 15 settimane In questo studio va sottolineata l’accuratezza dello staging che è stato effettuato mediante TC, EUS e LAPAROSCOPIA
  • “ Many surgeons are concerned that further delays will lead to more difficulty with the operation, including fibrosis. We did not encounter any such additional difficulties, either anecdotally or as reflected in intraoperative blood loss” Tran
  • Female, 39 years old Laparotomia esplorativa (6 aprile u.s.): Non resecabilità per infiltrazione del pilastro diaframmatico e del tripode celiaco Re-Staging CT
  • Transcript

    • 1. The road to R0 Several paths for one goal ? Domenico D’UGO Full Professor of Surgery Catholic University - Rome
    • 2. Survival after R0-Resection 36.1% German Gastric Cancer Study (1654 pts); Ann Surg, 1998 5 yrs
    • 3. Memorial Sloan-Kettering Cancer Center, New York (1172 pts); Ann Surg, 2004 7% 92% Recurrence after R0-Resection
    • 4. Personal Series (294 pts) – D. D’Ugo 2009 Risk factors pT3-4 pN+ diffuse type G3 larger size proximal site Time to recurrence months 19.0% 16.7% 39.3% 25.0% Peritoneal Lymph nodal Haematogenous Locoregional 60.7% Recurrence after R0-Resection Locoregional 19.1 Lymph nodal 24.2 Peritoneal 19.9 Haematogenous 25.9
    • 5. or Recurrence (of disease) Failure (of treatment) “ It’s what the surgeon doesn’t see that kills the patients” Sugarbaker PH J Nippon Med Sch. 2000 Feb;67(1):5-8 ?
    • 6. No residual disease , “ high probability” of cure The curative potential of gastric resection T1 or T2 N0 treated by D1, 2, 3 resection N1 treated by D2, 3 resection M0, P0, H0, CY0 Proximal and Distal margins >10 mm CRITERIA Japanese Gastric Cancer Association, 1998 D>N
    • 7. Nishi M, et al. Gastric Cancer, 1993 1962 General Rules for Gastric Cancer Study in Surgery and Pathology Survival after R0-Resection according to the “Japanese Rules”
    • 8. N0 patients N+ Patients
    • 9. Randomized Controlled Trials No survival benefit Dutch MRC
    • 10.  
    • 11. Maruyama Index: paradigm of tailored extension of LND Median MI = 26
    • 12. Chance of detecting lymph node metastases “ Calculating the probability of detecting metastases ... this probability increased steeply in the lower range and more gradually in the higher range yield”
    • 13. Overall survival: p=0.041 Disease-free survival: ns Cancer specific survival: ns Per-protocol analysis: OS, CSS, DFS: p=ns
    • 14. Overall survival: p=ns Disease-free survival: p= ns
    • 15. 36.1% Siewert 1998 64.8% Kim 1998 ≈ ≈ German Gastric Cancer Study (1654 pts); Ann Surg, 1998 Korea Gastric Cancer Center (10783 pts); Gastric Cancer, 1998 The E/W Survival Gap
    • 16. Magic Trial INT-0116 ACTS-GC CH-RT ECF courtesy by : T. SANO (2009) The E/W Survival Gap
    • 17. 2004 2005 2006 2008 “ Induction ” of R0
    • 18. “ Induction” of R0 by Neoadjuvant Chemotherapy Staging Laparoscopy
    • 19. D2 Lymphadenectomy “ Induction” of R0 by Neoadjuvant Chemotherapy
    • 20. Neoadjuvant Chemotherapy with Epirubicin, Etoposide and Cisplatin: 7-year follow-up 84% 58% 46% R0-Resection Rate: 83%
    • 21. 60% 36% T-downstaging: 42% = Induction of R0 Resection ? Neoadjuvant Chemotherapy with Epirubicin, Etoposide and Cisplatin: 7-year follow-up
    • 22.  
    • 23.  
    • 24. Circumferential Margin at EGJ The high proportion of “open & close” laparotomies” (12%) and of positive circumferential resection margin (32-47%) highlights limitations in the current staging techniques for identifying patients at risk for potential CRM involvement. Davies et al., Dis Esoph (2008) Dexter et al., GUT (2001)
    • 25. Preoperative radiotherapy : RCT – chinese report, 1998 “ Preoperative radiation therapy is able to improve the results of surgery for adenocarcinoma of the gastric cardia” Treatment: 40 Gy / 4 weeks by 2 Gy qd x 20 OS: 30% vs 19% Zhang, et al. Int. J. Radiation Oncology Biol. Phys., 1998
    • 26. Arm A : 2.5 PLF(cisplatin+fluorouracil+leucovorin) Arm B : 2 PLF+ cisplatin+etoposide+30 Gy “ Although the study was closed early and statistical significance was not achieved, results point to a survival advantage for preoperative chemo-radiotherapy compared with preoperative chemotherapy in adenoca. of the EGJ ” Preoperative Chemoradiation
    • 27. Preoperative Chemoradiation : RTOG 9904 Trial Ajani J, et al. J Clin Oncol 2006, 24, p3953 Pathologic Complete Response : 26%
    • 28. Ajani J, et al. J Clin Oncol 2006, 24, p3953 “ With some guideline refinements, the preoperative chemoradiotherapy strategy is poised for a comparison with postoperative chemoradiotherapy in patients with localized gastric cancer” 71% Preoperative Chemoradiation : RTOG 9904 Trial
    • 29. Preoperative Chemoradiation Fujitani K, Ajani J, et al. Ann Surg Oncol 2007, 14, p1305 Morbidity rate: 38.0% (27 patients) Mortality rate: 2.8% (2 patients) Prospectively collected database on 71 consecutive patients Induction chemotherapy chemo-radiotherapy (45 Gy) Postoperative results (…careful consideration of added risk…)
    • 30. Tran CL, et al. Am J Surg 2006, 192, p873 For Colorectal Cancer Francois Y, et al. J Clin Oncol 1999, 8, p2396 Multimodal Preoperative Treatment: Surgical Implications Delayed surgery… … increases probability of downstaging of the tumor when there is a correctly long interval between the completion of therapy and surgery … doesn’t modify toxicity and early clinical results diverting stoma avoids major morbidity due to anastomotic leak (fatal in 0-3% of cases) but… Matthiessen P, et al. Ann Surg 2007, 246, p207
    • 31.  
    • 32. For Gastric Cancer Bozzetti F, et al. Ann Surg 1997, 226, p613 Delayed surgery… … increases probability of downstaging of the tumor when there is a long interval between the completion of therapy and surgery … doesn’t modify toxicity and early clinical results No tools to avoid major morbidity due to anastomotic leak (fatal up to 1/3 of cases!) but… Sauvanet A, et al. J Am Coll Surg. 2005, 201 (2):p253 Multimodal Preoperative Treatment: Surgical Implications
    • 33. Multimodal Preoperative Treatment: Extreme Salvage Surgery FOX-RT for Previously Unresectable Disease
    • 34. Conclusions Multimodal preop. approach with delayed surgery… … is only seldom associated with tumor progression - accurate pretreatment staging? - radiation therapy optimization? … no increase of surgical morbi/ /mortality in experienced hands - high volume – post-RT surgery … doesn’t modify toxicity and early clinical results

    ×